Re-evaluating Antibiotic Therapy Duration for Infective Endocarditis: The POET-II Trial
The POET-II trial investigates the duration of antibiotic therapy for infective endocarditis, a condition traditionally treated with prolonged intravenous antibiotics. The study aims to determine if shorter regimens can be as effective while reducing side effects and resistance risks.
Why it matters
Standardizing shorter antibiotic treatments could significantly improve patient outcomes and reduce healthcare costs associated with long-term hospital stays.
Authors: Shashank Shekhar, 1 Seshasayee Narasimhan, 2 *Harish Ramakrishna 3
1. Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Ohio, USA 2.Department of Cardiology, Manning Base Hospital, Taree, Australia 3.Division of Cardiovascular and Thoracic Anesthesiology, Department of Anesthesia and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA *Correspondence to [email protected]
Disclosure: The authors have declared no conflicts of interest.
Keywords: Antibiotic therapy, infective endocarditis (IE), response-tailored therapy
Citation: EMJ Cardiol. 2026;14[1]:31-34. https://doi.org/10.33590/emjcardiol/1U8BD088
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in